Changed name from Auris Medical Holding to Altamira Therapeutics
EARS - Auris Medical Holding Ltd.
NASDAQ
->
Healthcare
->
Biotechnology
Hamilton,
Bermuda
Type: Equity
EARS price evolution
EARS
| (in millions $) | 30 Dec 2020 | 29 Sep 2020 | 29 Jun 2020 | 30 Mar 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $11.26 | $11.26 | $0.04 | $0.04 |
| Short term investments | ||||
| Net receivables | $0.06 | $0.06 | $0.15 | $0.15 |
| Inventory | ||||
| Total current assets | $11.62 | $11.62 | $0.39 | $0.39 |
| Long term investments | ||||
| Property, plant & equipment | $0.05 | $0.05 | $0.05 | $0.05 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $7.86 | |||
| Total investments | ||||
| Total assets | $20.8 | $20.8 | $7.96 | $7.96 |
| Current liabilities | ||||
| Accounts payable | $0.72 | $0.72 | $1.26 | $1.26 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3.03 | $3.03 | $2.42 | $2.42 |
| Long term debt | $0.05 | $0.05 | ||
| Total noncurrent liabilities | $1.1 | |||
| Total debt | ||||
| Total liabilities | $4.03 | $4.03 | $3.49 | $3.49 |
| Shareholders' equity | ||||
| Retained earnings | -$160.64 | -$160.64 | -$155.35 | -$155.35 |
| Other shareholder equity | $0.06 | $0.06 | -$0.01 | -$0.01 |
| Total shareholder equity | $16.77 | $16.77 | $4.48 | $4.48 |
| (in millions $) | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 | 30 Dec 2017 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $11.26 | $1.38 | $5.39 | $14.97 |
| Short term investments | ||||
| Net receivables | $0.06 | $0.23 | $0.22 | $0.14 |
| Inventory | ||||
| Total current assets | $11.62 | $2.37 | $6.06 | $15.87 |
| Long term investments | ||||
| Property, plant & equipment | $0.05 | $0.07 | $0.03 | $0.25 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $9.79 | $6.9 | $3.9 | $1.99 |
| Total investments | ||||
| Total assets | $20.8 | $9.23 | $9.88 | $17.83 |
| Current liabilities | ||||
| Accounts payable | $0.72 | $0.91 | $1.81 | $1.03 |
| Deferred revenue | ||||
| Short long term debt | $1.44 | $4.54 | ||
| Total current liabilities | $3.03 | $2.28 | $4.56 | $10.43 |
| Long term debt | $5.58 | |||
| Total noncurrent liabilities | $1.07 | $0.92 | $1.7 | $9.72 |
| Total debt | ||||
| Total liabilities | $4.03 | $3.19 | $6.23 | $19.99 |
| Shareholders' equity | ||||
| Retained earnings | -$160.64 | -$152.78 | -$146.3 | -$136.13 |
| Other shareholder equity | $0.06 | -$0.03 | -$0.04 | -$0.03 |
| Total shareholder equity | $16.77 | $6.04 | $3.65 | -$2.16 |
| (in millions $) | 30 Apr 2021 | 30 Dec 2020 | 29 Sep 2020 | 29 Jun 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $0.97 | $0.97 | $0.44 | |
| Selling, general & administrative | $0.56 | $0.56 | $0.76 | |
| Total operating expenses | $1.43 | $1.43 | $1.21 | |
| Operating income | -$1.43 | -$1.43 | -$1.21 | |
| Income from continuing operations | ||||
| EBIT | -$1.43 | -$1.43 | -$1.21 | |
| Income tax expense | -$0.01 | -$0.01 | -$0.01 | |
| Interest expense | -$0.07 | -$0.07 | -$0 | |
| Net income | ||||
| Net income | -$2.77 | -$2.77 | -$1.33 | |
| Income (for common shares) | -$2.77 | -$2.77 | -$1.33 | |
| (in millions $) | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 | 30 Dec 2017 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $2.83 | $3.3 | $6.62 | $19.1 |
| Selling, general & administrative | $2.63 | $3.95 | $4.3 | $5.24 |
| Total operating expenses | $5.28 | $7.26 | $10.95 | $24.36 |
| Operating income | -$5.28 | -$7.26 | -$10.95 | -$24.36 |
| Income from continuing operations | ||||
| EBIT | -$5.28 | -$7.26 | -$10.95 | -$24.36 |
| Income tax expense | -$0.02 | -$0.19 | $0.16 | -$0.02 |
| Interest expense | -$0.14 | -$0.03 | -$1.07 | -$1.64 |
| Net income | ||||
| Net income | -$8.2 | -$6.63 | -$11.5 | -$24.41 |
| Income (for common shares) | -$8.2 | -$6.63 | -$11.5 | -$24.41 |
| (in millions $) | 30 Dec 2020 | 29 Sep 2020 | 29 Jun 2020 | 30 Mar 2020 |
|---|---|---|---|---|
| Net income | -$2.77 | -$2.77 | -$1.33 | -$1.33 |
| Operating activities | ||||
| Depreciation | $0 | $0 | $0.01 | $0.01 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$1.61 | -$1.61 | -$0.81 | -$0.81 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.78 | -$0.78 | -$0.38 | -$0.38 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | $0.74 | $0.74 | $0.03 | $0.03 |
| Total cash flows from financing | $7.96 | $7.96 | $0.52 | $0.52 |
| Effect of exchange rate | $0.04 | $0.04 | $0 | $0 |
| Change in cash and equivalents | $5.61 | $5.61 | -$0.67 | -$0.67 |
| (in millions $) | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 | 30 Dec 2017 |
|---|---|---|---|---|
| Net income | -$8.2 | -$6.63 | -$11.5 | -$24.41 |
| Operating activities | ||||
| Depreciation | $0.02 | $0.03 | $0.07 | $0.12 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$4.84 | -$8.39 | -$13.23 | -$24.28 |
| Investing activities | ||||
| Capital expenditures | -$0.06 | -$0.06 | -$0.01 | |
| Investments | ||||
| Total cash flows from investing | -$2.31 | -$3 | -$1.82 | -$0.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | $1.52 | -$1.46 | -$9.27 | -$2.09 |
| Total cash flows from financing | $16.96 | $7.38 | $5.73 | $8.22 |
| Effect of exchange rate | $0.07 | $0.01 | -$0.26 | -$1.32 |
| Change in cash and equivalents | $9.87 | -$4.01 | -$9.58 | -$17.47 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.24 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.83 |
| Quick ratio | N/A |